Biotech · Public company · Cranbury, NJ, US
Palatin Technologies Inc
Ticker PTN · SEC CIK 0000911216
Track this companyFree. Adds Palatin Technologies Inc to your Dealase workspace and tells you when its record changes.
Clinical trials82 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline10
- BremelanotidePhase 3 · Hypoactive Sexual Desire DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PL9643 Ophthalmic SolutionPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle Ophthalmic SolutionPhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
- bremelanotidePhase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- BremelanotidePhase 2 · Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PL-3994 Aqueous Intravenous Solution Dose AscentionPhase 2 · Heart Failure With Preserved Ejection FractionClinicalTrials.gov · fetched Nov 12, 2026
- PL-3994 Aqueous Intravenous Solution Single DosePhase 2 · Heart Failure With Preserved Ejection FractionClinicalTrials.gov · fetched Nov 12, 2026
- PL8177Phase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- RAAS inhibition therapyPhase 2 · Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- tirzepatidePhase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 5, 2024ClinicalTrials.gov NCT06565611 · fetched Nov 12, 2026
- A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseasePHASE2 · COMPLETED · started Dec 26, 2022ClinicalTrials.gov NCT05709444 · fetched Nov 12, 2026
- Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 15, 2022ClinicalTrials.gov NCT05466890 · fetched Nov 12, 2026
- A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry EyePHASE3 · COMPLETED · started Dec 30, 2021ClinicalTrials.gov NCT05201170 · fetched Nov 12, 2026
- Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure SubjectsPHASE2 · TERMINATED · started Nov 12, 2020ClinicalTrials.gov NCT04318145 · fetched Nov 12, 2026
- Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry EyePHASE2 · COMPLETED · started Feb 14, 2020ClinicalTrials.gov NCT04268069 · fetched Nov 12, 2026
- 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderPHASE3 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02338960 · fetched Nov 12, 2026
- 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderPHASE3 · COMPLETED · started Dec 1, 2014ClinicalTrials.gov NCT02333071 · fetched Nov 12, 2026
SEC filings12
- 10-K · 10-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Feb 17, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Dec 19, 2025 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 12, 2025 · fetched Nov 12, 2026
- 424B4 · 424B4SEC EDGAR · filed Nov 12, 2025 · fetched Nov 12, 2026
- 424B4 · 424B4SEC EDGAR · filed Nov 10, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026
- S-1/A · FORM S-1/ASEC EDGAR · filed Oct 17, 2025 · fetched Nov 12, 2026